allodynia semaglutide treatment versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial ⚠️ New Sensory Side Effects

Eli Lilly's latest data release follows the company's earlier findings, released in early August, that showed that trial participants who are overweight or have obesity lost an average of 27 pounds or about 12.4% of their body weight after taking Eli Lilly's oral daily GLP-1 pill -- orforglipron -- for at least 72 weeks

PlexusDx partners with prescribers to create personalized weight loss plans that align with your postpartum recovery journey

Here's what you should prioritize, according to Tsang

At Ministry of Faces in Leeds, we prioritise safety by using high-quality products specifically designed to break down fat cells effectively

Moreover, the inconvenience and discomfort associated with subcutaneous injection could negatively impact medication adherence ( Oral formulations of GLP-1 RAs enhance treatment convenience, acceptance, and adherence, offering patients an alternative option to achieve glycemic goals without injections (Thethi et al., 2020)